Learn how consolidation durvalumab after sequential chemoradiotherapy demonstrated favorable long-term survival and a manageable safety profile in unresectable stage III NSCLC in the PACIFIC-6 trial.
Read More
Learn how consolidation durvalumab after sequential chemoradiotherapy demonstrated favorable long-term survival and a manageable safety profile in unresectable stage III NSCLC in the PACIFIC-6 trial.
Read MoreExplore the latest NSCLC research on guideline-concordant care, biomarker testing, social determinants of health, patient distress, and survival disparities from ASCO 2025.
Read MoreExplore a meta-analysis comparing nonintubated and intubated VATS for NSCLC lobectomy, including complications, recovery, surgical outcomes, and oncologic safety.
Read MoreExplore recent NSCLC research on biomarkers, EGFR mutations, ctDNA, surgery, radiation risks, antibiotics, and diagnostic testing.
Read MoreResearch Summary: KRAS G12C mutations occur in a substantial subset of advanced non-small cell lung cancer (NSCLC), and current first-line standards based on immune checkpoint inhibitors (ICIs), with or without chemotherapy, yield suboptimal long-term outcomes. Olomorasib is an orally bioavailable, highly selective KRAS G12C inhibitor...
Read MoreReprinted with permission. Biomedicines. 2025;13(9):2142.* by Peter Manolakos, Yu-Bo Wang, Janice Withycombe, Luigi Boccuto, and Diana Ivankovic Dr. Manolakos is with Healthcare Genetics and Genomics PhD Program, Clemson University in Clemson, South Carolina. Dr. Bo-Wang is with School of Mathematical and Statistical Sciences, Clemson University...
Read MoreExplore recent research on KRAS-mutant lung cancer, including immune escape, biomarker testing, treatment outcomes, and prognostic biomarkers.
Read More©2026 Oncology Matrix. All Rights Reserved.